
Michael Antonov: From Virtual World Builder to Real-World Drug Designer
AI is transforming biomedical research, but meaningful advances in drug discovery require more than just increasingly powerful algorithms—they depend on combining machine learning with physics-based simulations, mechanistic models, and rigorous experimental validation. In this episode of Behind the Breakthroughs, Michael Antonov, co-founder of Oculus and computational drug discovery company Deep Origin, shares a pragmatic perspective on AI's opportunities and limitations in medicine, explaining where it is accelerating innovation and why human expertise and experimental science remain indispensable.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
Medicine is full of breakthroughs. Most don't become medicine. Behind the Breakthroughs explores scientific ideas that could change how we diagnose and treat disease—and what it will take for them to work. Host Jonathan D. Grinstein, PhD, a scientist-turned-journalist, speaks with the researchers, physicians, and entrepreneurs building the next generation of genetic medicines, diagnostics, AI, precision therapeutics, and biotechnology.
Hosted on Acast. See acast.com/privacy for more information.
More episodes from "Behind the Breakthroughs"



Don't miss an episode of “Behind the Breakthroughs” and subscribe to it in the GetPodcast app.








